On September 29, DUALITYBIO-B rose 5.34% in regular trading, trading at 204.0 HKD/share, with turnover of approximately 31.30 million HKD. The gain was primarily driven by the upcoming ESMO Annual Meeting scheduled for late October in Madrid, alongside a broader rally in the biotech sector.

According to the latest disclosed conference agenda, 32 China-origin clinical studies were featured among breakthrough abstracts, accounting for over 30% of the total, with ADC pipeline presentations drawing heightened market expectations. DUALITYBIO-B's core candidate DB-1311, developed under a global collaboration with Roche's Genentech, recently presented combination data at the WCLC conference, reinforcing investor interest in its IO2.0+ADC strategy. The Genentech partnership, announced in late August, includes a 45 million USD upfront payment and potential milestone payments exceeding 1 billion USD.

Within the Biotechnology sector, AKESO led gains at 13.15%, followed by KEYMED BIO-B up 7.11%, BEONE MEDICINES up 2.76%, 3SBIO up 2.37%, and INNOVENT BIO up 0.78%, reflecting broad sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)